CD86 and neoplasm: Next, we analyzed tumor samples from all treatment groups for M1 and M2 macrophage markers (CD86 and CD206 respectively), as well as for CD8+ T cell infiltration and activation using immunofluorescence and FC analysis (gating strategies in Supplementary Fig. 7l).